With its proprietary π-Icosa High-capacity and High-precision AAV serotype screening platform PackGene aims to identify tissue-specific and maximally infective AAV serotypes for clinical trial development. High infectivity and tissue specificity can ultimately reduce the dosage and production cost of AAV-based gene therapies while simultaneously increasing safety and efficacy.
![icon-6](https://static.packgene.com/wp-content/uploads/2023/09/icon-6.png)
Capacity
Our platform design results in higher library capacity
![icon-3](https://static.packgene.com/wp-content/uploads/2023/09/icon-3.png)
Precision
Higher precision AAV-serotype screening
![icon-11](https://static.packgene.com/wp-content/uploads/2023/09/icon-11.png)
Efficacy
High infectivity and tissue specificity can result in reduced dosage requirements that increase both safety and efficacy.
PackGene has three patents pending.
![tissue targeting aav tissue targeting aav](https://static.packgene.com/wp-content/uploads/2022/10/image-scaled-1.jpg)
- Library>1 billion mutants
- Screens AAVs for tissue specificity.